Singapore markets closed
Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,158.71 +30.92 (+0.60%) Dow
38,818.26 +142.58 (+0.37%) Nasdaq
16,250.68 +94.35 (+0.58%) Bitcoin USD
64,009.04 +142.14 (+0.22%) CMC Crypto 200
1,376.43 +63.80 (+4.86%)
ABT Nov 2024 85.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:42AM EDT. Market open.
| Previous close | 0.9900 |
| Open | 0.9900 |
| Bid | 0.8400 |
| Ask | 0.9600 |
| Strike | 85.00 |
| Expiry date | 2024-11-15 |
| Day's range | 0.9900 - 0.9900 |
| Contract range | N/A |
| Volume | |
| Open interest | 170 |
ZacksIs Trending Stock Abbott Laboratories (ABT) a Buy Now?
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
ZacksPBH vs. ABT: Which Stock Is the Better Value Option?
PBH vs. ABT: Which Stock Is the Better Value Option?
PR NewswireAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
© 2024 Yahoo. All rights reserved.